Featured Research

from universities, journals, and other organizations

Estimate of a quarter of a million deaths annually vastly underestimates true burden of rheumatic heart disease

Date:
September 26, 2013
Source:
World Heart Federation
Summary:
A paper analyses the burden of disease and suggests that numbers published to date of global deaths from rheumatic heart disease (ranging from at least 233,000 deaths per year upwards) could be substantially underestimating reality, for a variety of reasons, most commonly lack of high quality (or in some cases any) data from high-prevalence countries and regions.

A paper in the RHD special issue of Global Heart, the journal of the World Heart Federation, analyses the burden of disease and suggests that numbers published to date (ranging from at least 233,000 deaths per year upwards) could be substantial underestimates for a variety of reasons, most commonly lack of high quality (or in some cases any) data from high-prevalence countries and regions. The paper is by Dr Liesl Zühlke, University of Cape Town and Red Cross War Memorial Children's Hospital, Cape Town, South Africa and Dr Andrew Steer, Centre for International Child Health at the University of Melbourne, Australia.

The authors say: "Currently available figures used to define the global burden of acute rheumatic fever and rheumatic heart disease, although crucial to control efforts, are imperfect. Data have been hindered by methodological differences between studies, by patchy coverage within countries and across regions, and by an incomplete understanding of the relationship between echocardiographic detection of asymptomatic mild disease and progression to symptomatic disease."

A WHO study published in 2005 found an overall global burden of 471,000 annual cases of ARF, with the incidence of acute rheumatic fever (ARF) ranging from 10 cases per 100,000 children aged 5 to 15 years in industrialised countries to 374 cases per 100,000 in the Pacific region. The overall burden of RHD was estimated to be 15.6 million prevalent cases with 282,000 new cases and over 233,000 deaths per year.

The recently published Global Burden of Disease Study reports that the number of years lived with disability (YLD) due to RHD was estimated in 2010 at 1 430 000*, equivalent to a quarter of the figure for all cancers combined. Lozarno and colleagues reported 345,100 deaths due to RHD in 2010 which represents a 25% reduction compared to 1990; with an age-standardised death rate of 5.2 per 100,000 which was a 53% reduction compared to1990. However, the authors caution that these figures should be viewed with caution and are currently being re-analysed for the next Global Burden of Disease analysis in 2014.

RHD burden of disease estimates also face the new problem of both more definite and borderline cases being diagnosed with echocardiogram equipment. The authors say: "It is perhaps time to change the way that we think about RHD and attempt to describe the disease burden with greater subtlety that takes into account our increasing understanding of the disease." Such a revised model might include an assessment of RHD burden in two categories: 1) Symptomatic disease which could also be called active disease; and 2) Asymptomatic disease which could also be called latent disease This approach has some similarities (but also obvious differences) to the model of disease applied to other latent diseases including infection with Mycobacterium tuberculosis.

The authors conclude: "Moving forward, it will be critical to generate high quality and comprehensive data regarding all aspects of the burden of ARF and RHD to better inform national, regional and global control strategies... New studies are underway in several high-prevalence sentinel areas in diverse geographic locations to address the need of contemporary data... These data will provide vital information in order to advocate even more strongly for directed funding and public health interventions to control ARF and RHD."


Story Source:

The above story is based on materials provided by World Heart Federation. Note: Materials may be edited for content and length.


Cite This Page:

World Heart Federation. "Estimate of a quarter of a million deaths annually vastly underestimates true burden of rheumatic heart disease." ScienceDaily. ScienceDaily, 26 September 2013. <www.sciencedaily.com/releases/2013/09/130926204714.htm>.
World Heart Federation. (2013, September 26). Estimate of a quarter of a million deaths annually vastly underestimates true burden of rheumatic heart disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/09/130926204714.htm
World Heart Federation. "Estimate of a quarter of a million deaths annually vastly underestimates true burden of rheumatic heart disease." ScienceDaily. www.sciencedaily.com/releases/2013/09/130926204714.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins